Full-Time

Global Clinical Development Lead

Targeted Alpha Therapeutics

Posted on 7/9/2024

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

No salary listed

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Medical degree required
  • Clinical experience in medical oncology or nuclear medicine is essential
  • Minimum of 5 years of experience in clinical development
  • Strong knowledge of clinical trial design, methodology, and regulatory requirements
  • Successful leadership and project management of clinical development programs
  • Experience with regulatory submissions (e.g., IND, CTA) and interaction with regulatory agencies (e.g., FDA, EMA) is preferred
Responsibilities
  • Lead development of clinical development plans for targeted alpha therapeutics
  • Collaborate with global program heads, regulatory affairs, medical affairs, and translational medicine teams to ensure alignment of clinical trial objectives with overall asset strategy
  • Develop clinical study plans from concept to synopsis to full protocol, ensuring alignment with the Company’s objectives, and the needs of regulatory authorities, healthcare professionals, patient groups, guidelines committees and payors
  • Develop – in collaboration with relevant cross-functional teams and medical writers – clinical study documentation including, but not limited to informed consent documents, imaging charters, study manuals and final regulatory dossiers.
  • Lead clinical scientific input into documentation including investigator brochures, IMPDs, safety reports (e.g. DSURs, PSURs, and SUSARs), clinical study reports and regulatory documents such as briefing packages, INDs, BLAs, NDAs and MAAs
  • Lead the analysis, review, and quality control of clinical data (e.g. study-related, aggregated) including efficacy, safety, and imaging data to ensure accuracy and quality
  • Prepare and deliver presentations, proposals, and reports for senior management, partners, and other stakeholders
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their approach helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations, aiming to create lasting value for patients, shareholders, and employees.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's priority review for TLX250-CDx indicates strong potential in kidney cancer imaging.
  • Promising IPAX-Linz study results for TLX101 could boost market share in neuro-oncology.
  • Acquisition of ImaginAb's platform allows exploration of new disease areas with radiotherapeutics.

What critics are saying

  • Increased competition from Novartis and Bayer may impact Telix's market share.
  • Supply shortages of isotopes like gallium-68 could affect product availability in Europe.
  • Regulatory hurdles in Asia may delay Telix's expansion into new markets.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and ethical practices into its operations and patient care.
  • Telix has a robust global supply chain ensuring product availability worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
PR Newswire
Apr 15th, 2025
Ipax-Linz Study Reports Promising Efficacy For Tlx101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]

Siam News Network
Apr 6th, 2025
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.

Telix Pharmaceuticals
Apr 3rd, 2025
Anne Whitaker Appointed as Non-Executive Director

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].

Pipeline Review
Apr 2nd, 2025
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).

Telix Pharmaceuticals
Mar 19th, 2025
EAU25: Telix presents at Europe's largest urological event

Join Telix this week at the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.

INACTIVE